Earth Science Tech (OTCQB: ETST) is leveraging its diversified conglomerate business model to build a vertically integrated healthcare platform while expanding its presence across real estate, asset management and consumer products. Its healthcare operations combine compounding pharmacies, telemedicine, clinical support and direct-to-patient fulfillment, supported by internal technology, proprietary physician networks and owned real estate. The company’s acquisition of Zoolzy LLC, a wholesale distributor of active pharmaceutical ingredients and FDA-approved prescription products, further strengthens supply chain control and provides its pharmacies with access to competitively priced ingredients. By bringing more operational functions in-house and leveraging the capabilities of its subsidiaries, Earth Science Tech aims to capture margins otherwise paid to outside providers while reducing exposure to individual sector risks. The strategy is reflected in its fiscal first-quarter 2026 results, with net income increasing 57% year over year and net cash provided by operating activities rising 108%, while all key operating subsidiaries remained profitable.
To view the full article, visit https://ibn.fm/3knvb
About Earth Science Tech Inc.
Earth Science Tech operates as a diversified holding company focused on the health and wellness sector. The company’s principal operating strategy is to build a vertically integrated healthcare platform that combines compounding pharmacy operations, telemedicine platforms, clinical support, and direct-to-patient fulfillment. The company’s healthcare operations are supported by investments in real estate and asset management activities and a consumer products business.
The core of the company’s value proposition is the seamless integration of patient care, from consultation to fulfillment. This is achieved through the synergy of specialized subsidiaries.
To learn more, please visit www.EarthScienceTech.com.
NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at https://ibn.fm/ETST
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN